B. Casslén

发表

Hormonal Regulation of the Release of Plasminogen Activators and of a Specific Activator Inhibitor from Endometrial Tissue in Culture

B. Casslén, I. Nilsson, B. Åstedt, 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Reduction of PAI-2 production in cultured human peripheral blood monocytes by estradiol and progesterone-no effect on t-PA, u-PA and PAI-1

B. Åstedt, B. Kinnby, B. Casslén, 1995 .

Release of proteolytic enzymes from leucocytes attached to IUDs.

K. Ohlsson, K. Lindholm, B. Åstedt, 1982, Contraception.

Proteinases and proteinase inhibitors in uterine fluid with special reference to IUD‐users

B. Casslén, B. Casslén, 1981, Acta obstetricia et gynecologica Scandinavica. Supplement.

Inhibitors of Trypsin, Chymotrypsin and Elastase in Human Uterine Fluid

B. Casslén, B. Casslén, 1986, Acta obstetricia et gynecologica Scandinavica.

Monoamine transporters in human endometrium and decidua.

B. Casslén, S. Hansson, B. Bottalico, 2008, Human reproduction update.

Transvaginal ultrasound and lactate dehydrogenase isoenzyme activity profile in uterine aspirate for diagnosis of endometrial carcinoma in women with postmenopausal bleeding

G. Lingman, K. Maršál, B. Casslén, 2006, International Journal of Gynecologic Cancer.

Diagnosis of endometrial cancer in patients with postmenopausal bleeding by analysis of the lactate dehydrogenase isoenzyme activity profile in uterine fluid.

K. Maršál, B. Casslén, G. Skude, 2004, Gynecologic oncology.

Free amino acids in human uterine fluid. Possible role of high taurine concentration.

B. Casslén, 1987, The Journal of reproductive medicine.

Cyclic Variation of Plasminogen Activation in Human Uterine Fluid and the Influence of an Intrauterine Device

K. Ohlsson, B. Casslén, 1981, Acta obstetricia et gynecologica Scandinavica.

The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua

B. Casslén, S. Hansson, H. Domanski, 2007, Molecular reproduction and development.

Plasma membrane and vesicular monoamine transporters in normal endometrium and early pregnancy decidua.

K. Maršál, B. Casslén, S. Hansson, 2003, Molecular human reproduction.

Human uterine fluid, examined in undiluted samples for osmolarity and the concentrations of inorganic ions, albumin, glucose, and urea.

B. Casslén, B. Nilsson, B. Casslén, 1984, American journal of obstetrics and gynecology.

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.

B. Casslén, B Casslén, T Bossmar, 1994, European journal of cancer.

Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms.

S. Ahmadi, V. Nosková, B. Casslén, 2009, Gynecologic oncology.

Cytologic atypias in the uterine fluid of intrauterine contraceptive device users.

B. Casslén, T. Kobayashi, N. Stormby, 1983, Acta cytologica.

Nuclear DNA content of atypical glandular cells in the uterine fluid of IUD users.

N. Tanaka, T. Ueno, T. Kobayashi, 1984, Acta cytologica.

Enzyme cytochemical studies of the mononuclear phagocytic cells in human uterine fluid.

T. Kobayashi, N. Stormby, B. Casslén, 1982, Analytical and quantitative cytology.

Cyclic variation of the cellular components in human uterine fluid.

T. Kobayashi, N. Stormby, B. Casslén, 1982, Journal of reproduction and fertility.

The cellular composition of uterine fluid in IUD users - a quantitative study.

B. Casslén, T. Kobayashi, N. Stormby, 1981, Contraception.

Reduced plasminogen activator content of the endometrium in oral contraceptive users.

B. Åstedt, B. Casslén, 1983, Contraception.

Fluid Characteristics of Benign Ovarian Cysts: Correlation With Recurrence After Puncture

B. Casslén, E. Andolf, C. Jörgensen, 1995, Obstetrics and gynecology.

Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.

A. Ehinger, B. Casslén, G. Høyer-Hansen, 2004, Molecular human reproduction.

Plasminogen activators in the human endometrium, cellular origin and hormonal regulation

T. Ny, I. Lecander, S. Urano, 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Cyclic variation of proteinase inhibitors in human uterine fluid and influence of an IUD.

K. Ohlsson, B. Casslén, 1981, Contraception.

Effect of IUD on urokinase-like immunoreactivity and plasminogen activators in human uterine fluid.

B. Casslén, J. Thorell, B. Åstedt, 1981, Contraception.

Fibrinolytic activity of human uterine fluid

B. Åstedt, B. Casslén, 1981, Acta obstetricia et gynecologica Scandinavica.

Occurrence of both urokinase and tissue plasminogen activator in the human endometrium.

B. Åstedt, B. Casslén, 1983, Contraception.

Platelet-activating factor in human luteal phase endometrium.

B. Casslén, D. Hanahan, R. Riehl, 1989, Biology of reproduction.

Endometrial TIMP-4 mRNA is expressed in the stroma, while TIMP-4 protein accumulates in the epithelium and is released to the uterine fluid.

B. Casslén, S. Hansson, H. Domanski, 2006, Molecular human reproduction.

Endometrial expression of the estrogen-sensitive genes MMP-26 and TIMP-4 is altered by a substitution protocol without down-regulation in IVF patients.

P. Eriksson, B. Casslén, S. Hansson, 2006, Human reproduction.

High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer

M. Fernö, P. Bendahl, S. Grénman, 2003, International journal of cancer.

High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI‐2) is an independent marker for shorter progression‐free survival in patients with early stage endometrial cancer

N. Brünner, M. Fernö, P. Bendahl, 2002, International journal of cancer.

Paracrine stimulation of capillary endothelial cell migration by endometrial tissue involves epidermal growth factor and is mediated via up-regulation of the urokinase plasminogen activator receptor.

A. Ehinger, B. Casslén, T. Sandberg, 2001, The Journal of clinical endocrinology and metabolism.

Human endothelial cell migration is stimulated by urokinase plasminogen activator:plasminogen activator inhibitor 1 complex released from endometrial stromal cells stimulated with transforming growth factor beta1; possible mechanism for paracrine stimulation of endometrial angiogenesis.

B. Gustavsson, B. Casslén, B. Gustavsson, 1998, Biology of reproduction.

Estrogens and postoperative thrombosis evaluated by the radioactive iodine method.

U. Ulmsten, B. Åstedt, K. Bernstein, 1980, Surgery, gynecology & obstetrics.

Implantation of the Human Embryo: Research Lines and Models

C. Simón, P. Bischof, N. Macklon, 2006, Gynecologic and Obstetric Investigation.

Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours.

B. Gustavsson, B. Casslén, B. Gustavsson, 1991, European journal of cancer.

Fibrinolytic activity of uterine fluid in iud‐users

B. Åstedt, B. Casslén, 1981, Acta obstetricia et gynecologica Scandinavica.

Normalizing to GADPH jeopardises correct quantification of gene expression in ovarian tumours – IPO8 and RPL4 are reliable reference genes

B. Casslén, S. Hansson, A. Arakelyan, 2013, Journal of Ovarian Research.

Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.

B. Casslén, G. Høyer-Hansen, K. Wahlberg, 1998, Cancer research.

Differential regulation of the plasminogen activator inhibitor-1 (PAI-1) gene expression by growth factors and progesterone in human endometrial stromal cells.

P. Eriksson, B. Casslén, B. Gustavsson, 1997, Molecular human reproduction.

Estradiol Attenuates EGF-Induced Rapid uPAR Mobilization and Cell Migration via the G-protein-Coupled Receptor 30 in Ovarian Cancer Cells

B. Casslén, G. Høyer-Hansen, S. Hansson, 2009, International Journal of Gynecologic Cancer.

Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer

I. Christensen, C. Borgfeldt, B. Casslén, 2008, Clinical Cancer Research.

EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.

M. Sixt, B. Casslén, G. Høyer-Hansen, 2006, Gynecologic oncology.

Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI‐1)

C. Borgfeldt, B. Gustavsson, B. Casslén, 2001, International journal of cancer.

Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer.

N. Brünner, M. Fernö, P. Bendahl, 2001, European journal of cancer.

The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer

A. Ehinger, K. Jirström, B. Casslén, 2012, Journal of Ovarian Research.

G protein-coupled estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and early pregnancy decidua.

A. Ehinger, B. Casslén, S. Hansson, 2010, Molecular human reproduction.

Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter (VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human placenta from pre-eclamptic and normotensive pregnancies.

K. Maršál, B. Casslén, S. Hansson, 2004, Placenta.

Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor.

L. Lund, B. Gustavsson, B. Casslén, 1995, The Journal of clinical endocrinology and metabolism.

Plasminogen activator inhibitor 2 in menstrual endometrium and in primary cultures of endometrial cells

B. Casslén, J. Nordengren, I. Lecander, 1996 .

Expression of cell membrane receptors for urokinase plasminogen activator (u-PA) in the human endometrium increases during the ovarian cycle

B. Casslén, B. Gustavsson, B. Casslén, 1991 .

High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer.

M. Fernö, P. Bendahl, C. Borgfeldt, 2003, Gynecologic oncology.

Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer.

P. Eriksson, B. Casslén, S. Hansson, 2004, Gynecologic oncology.

Fibrinolytic activity of uterine fluid in oral contraceptive users.

B. Casslén, 1982, Contraception.

Degradation of urokinase plasminogen activator (UPA) in endometrial stromal cells requires both the UPA receptor and the low-density lipoprotein receptor-related protein/alpha2-macroglobulin receptor.

B. Angelin, B. Casslén, B. Gustavsson, 1998, Molecular human reproduction.

Progesterone regulation of plasminogen activator inhibitor 1 (PAI-1) antigen and mRNA levels in human endometrial stromal cells.

B. Casslén, T. Ny, S. Urano, 1992, Thrombosis research.

Hormonal Regulation of Plasminogen Activation in the Human Endometrium

B. Casslén, B. Casslén, 1992 .

Localization and quantitation of a low molecular weight proteinase inhibitor, antileukoprotease, in the human uterus.

K. Ohlsson, B. Casslén, M. Rosengren, 1981, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

Occurrence of the specific plasminogen activator inhibitor of placental type, PAI-2 in ascitic fluid and tumour vessel blood from patients with ovarian carcinoma

B. Casslén, P. Andreasen, B. Åstedt, 1990 .

Transforming growth factor beta1 in the human endometrium. Cyclic variation, increased expression by estradiol and progesterone, and regulation of plasminogen activators and plasminogen activator inhibitor-1.

R. Willén, B. Casslén, B. Gustavsson, 1998, Biology of reproduction.

Proteinases and Proteinase Inhibitors in Human Endometrial Secretion

B. Casslén, 1985 .

Endometrial TIMP-4 mRNA is high at midcycle and in hyperplasia, but down-regulated in malignant tumours. Coordinated expression with MMP-26.

P. Eriksson, B. Casslén, S. Hansson, 2004, Molecular human reproduction.

Epithelial expression of matrix metalloproteinase-26 is elevated at mid-cycle in the human endometrium.

P. Eriksson, B. Casslén, S. Hansson, 2003, Molecular human reproduction.

High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer

C. Borgfeldt, B. Casslén, G. Kalapotharakos, 2012, Journal of Ovarian Research.

Progesterone regulation of prolactin release from human endometrial stromal cells in culture: potential bioassay for progestational activity.

M. Harper, T. Siler-Khodr, B. Casslén, 1990, Acta endocrinologica.

Histamine uptake by human endometrial cells expressing the organic cation transporter EMT and the vesicular monoamine transporter-2.

A. Ehinger, B. Casslén, S. Hansson, 2006, Molecular human reproduction.

High preoperative blood levels of HE 4 predicts poor prognosis in patients with ovarian

C. Borgfeldt, B. Casslén, G. Kalapotharakos, 2012 .

High tissue content of urokinase plasminogen activator (u‐PA) is associated with high stromal expression of u‐PA mRNA in poorly differentiated serous ovarian carcinoma

C. Borgfeldt, B. Casslén, B. Åstedt, 1998, International journal of cancer.

Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u‐PA, t‐PA) in endometrial carcinoma

B. Gustavsson, R. Willén, B. Casslén, 1998, International journal of cancer.

Rebound increase of PAI‐1 following local intra‐arterial rt‐PA infusion, a possible cause of reocclusion

L. Norgren, B. Åstedt, I. Lecander, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.